Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125,000 people of more than 140 nationalities work at Novartis around the world.
Business & Industry
- Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
- Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
- Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
- Bayer Consumer Health leaders propose new principles for science-led self-care
- GSK signs agreement to support pandemic preparedness in Europe
Research & Development
- New method of nasal vaccine delivery could lead to better vaccines for HIV and COVID-19
- Research identifies, exploits vulnerability in certain high-risk cancers
- Scientists create long-acting injectable drug delivery system for tuberculosis
- Treating cancer by sticking cells in place
- Vitamin K prevents cell death: a new function for a long-known molecule
- Disparities in United States COVID-19 vaccine distribution
- New needle-free nasal vaccine shows promise for COVID-19
Conferences & Events
- New approach to treatment of deadly kidney cancer
- SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
- Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
- SMi's 22nd Annual Pain Therapeutics Conference
- SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
- SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
- SMi's 3rd Annual AI in Drug Discovery Conference
Regulatory Affairs
- FDA approves first systemic treatment for alopecia areata
- FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
- FDA limits use of Janssen COVID-19 vaccine to certain individuals
- EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
- FDA approves first generic of Symbicort to treat asthma and COPD